Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer

類似資料

• Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib
  著者:: Noeparast, Amir, 等
  出版事項: (2016)
• CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition
  著者:: Noeparast, Amir, 等
  出版事項: (2019)
• RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF
  著者:: Poulikakos, Poulikos I., 等
  出版事項: (2010)
• Targeting USP13‐mediated drug tolerance increases the efficacy of EGFR inhibition of mutant EGFR in non‐small cell lung cancer
  著者:: Giron, Philippe, 等
  出版事項: (2021)
• An alternative model for (breast) cancer predisposition
  著者:: Teugels, Erik, 等
  出版事項: (2017)